Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INMB
- Price
- 7.38
- Stock movement up
- +0.65 (9.66%)
- Company name
- INmune Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 163.63M
- Ent value
- 144.19M
- Price/Sales
- 3896.03
- Price/Book
- 4.23
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.52%
- 1 year return
- -31.92%
- 3 year return
- -3.57%
- 5 year return
- 17.46%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INMB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3896.03 |
| Price to Book | 4.23 |
| EV to Sales | 3433.05 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 22.17M |
| EPS (TTM) | -2.04 |
| FCF per share (TTM) | -1.28 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 42.00K |
| Gross profit (TTM) | 42.00K |
| Operating income (TTM) | -41.55M |
| Net income (TTM) | -41.27M |
| EPS (TTM) | -2.04 |
| EPS (1y forward) | -2.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -98921.43% |
| Profit margin (TTM) | -98266.67% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 33.55M |
| Net receivables | 1.42M |
| Total current assets | 35.85M |
| Goodwill | 0.00 |
| Intangible assets | 16.51M |
| Property, plant and equipment | 335.00K |
| Total assets | 52.78M |
| Accounts payable | 10.64M |
| Short/Current long term debt | 2.91M |
| Total current liabilities | 13.82M |
| Total liabilities | 14.11M |
| Shareholder's equity | 38.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -25.75M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -25.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -106.71% |
| Return on Assets | -78.19% |
| Return on Invested Capital | -99.92% |
| Cash Return on Invested Capital | -62.34% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.75 |
| Daily high | 7.47 |
| Daily low | 6.54 |
| Daily Volume | 244K |
| All-time high | 27.85 |
| 1y analyst estimate | 19.83 |
| Beta | 1.85 |
| EPS (TTM) | -2.04 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| INMB | S&P500 | |
| Current price drop from All-time high | -73.50% | -12.89% |
| Highest price drop | -84.20% | -56.47% |
| Date of highest drop | 20 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -55.08% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 904 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
163.63M
Marketcap category
Small-cap
Description
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Employees
11
Website
Investor relations
-
SEC filings
CEO
Raymond J. Tesi
Country
USA
City
La Jolla
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
INmune Bio, Inc. (NASDAQ:INMB) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ETCompany ParticipantsDavid Moss - CFORaymond Tesi - CEO &...
August 2, 2024
iO Charts is a Seeking Alpha partnerNext page